PERFORMANE
PEG-MGF
Subcutaneous injection
Overview
PEG-MGF is a pegylated derivative of Mechano Growth Factor designed to extend systemic half-life through the addition of polyethylene glycol moieties. Pegylation reduces renal clearance and proteolytic degradation, theoretically allowing for less frequent dosing and broader tissue distribution compared to unmodified MGF.
Mechanism of Action
The modified peptide retains the proposed satellite cell activation properties of native MGF.
​Research Summary & Key Findings
No published clinical or preclinical studies have characterized the pharmacology, safety, or efficacy of PEG-MGF in any species. Available information is derived from unverified commercial sources and anecdotal reports. This compound has not been subjected to regulatory review and remains wholly investigational.
Clinical Status
FDA APPROVED
PEG-MGF is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
Subcutaneous injection (weekly)
Administration Routes
METABOLIC
Semaglutide (Ozempic/Wegovy)
METABOLIC
An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds…
METABOLIC
Tirzepatide (Mounjaro/Zepbound)
A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways…
METABOLIC
AOD-9604
A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604…
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.